Sign In
Buy PTCT
$68.68
+0.450 (+0.660%)
At Close: Jun 03, 2026
PTC Therapeutics Takes Investors On A Ride With A Failed Study, Scrapped Programs, Ousted CFO
05:36pm, Tuesday, 23'rd May 2023
PTC stock crashed late Tuesday after the company's treatment for a neurological disorder flunked in a Phase 3 study. The post PTC Therapeutics Takes Investors On A Ride With A Failed Study, Scrapped P
PTC Therapeutics' (PTCT) PKU Drug Meets Study Goal, Up 7.6%
02:34pm, Thursday, 18'th May 2023
Data from a late-stage study data shows that treatment with PTC Therapeutics' (PTCT) sepiapterin led to a significant reduction in Phe levels in PKU patients. Post the news, share price rises.
Why PTC Therapeutics Could Be Victorious In Its Rare-Disease Battle Against BioMarin Pharmaceuticals
10:01am, Wednesday, 17'th May 2023
PTC stock surged Wednesday after the company unveiled promising results for its rare disease treatment, a rival to BioMarin's Kuvan. The post Why PTC Therapeutics Could Be Victorious In Its Rare-Disea
PTC Therapeutics, Inc. (PTCT) Q1 2023 Earnings Call Transcript
01:20am, Friday, 28'th Apr 2023
PTC Therapeutics, Inc. (PTCT) Q1 2023 Earnings Call Transcript.
PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates
07:01pm, Thursday, 27'th Apr 2023
PTC Therapeutics (PTCT) came out with a quarterly loss of $1.88 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to loss of $1.78 per share a year ago.
PTC Therapeutics (PTCT) Upgraded to Buy: What Does It Mean for the Stock?
01:42pm, Thursday, 27'th Apr 2023
PTC Therapeutics (PTCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PTC Therapeutics Announces CEO Stuart Peltz Is Resigning
09:55am, Saturday, 25'th Mar 2023
Stuart Peltz, Ph.D., founding Chief Executive Officer (CEO) of PTC Therapeutics announced that he is stepping down after 25 years.
PTC Therapeutics, Inc. (PTCT) Q4 2022 Earnings Call Transcript
10:35pm, Tuesday, 21'st Feb 2023
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q4 2022 Earnings Conference Call February 21, 2023 4:30 PM ET Company Participants Kylie O'Keefe - Chief Commercial Officer Stuart Peltz - Chief Executive Officer
PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates
06:49pm, Tuesday, 21'st Feb 2023
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -19.90% and 6.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
04:30pm, Tuesday, 07'th Feb 2023
SOUTH PLAINFIELD, N.J. , Feb. 7, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full y
PTC Therapeutics: Overdependence On One Asset, Poor Cash Management
05:19am, Monday, 30'th Jan 2023
PTCT is a commercial stage small cap surviving on a timely loan. Their revenue stream is overdependent on one franchise.
PTC Therapeutics (PTCT) Soars 5.8%: Is Further Upside Left in the Stock?
06:02am, Tuesday, 10'th Jan 2023
PTC Therapeutics (PTCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near
7 Nasdaq Stocks to Sell Before They Plunge in 2023
03:47pm, Monday, 05'th Dec 2022
While the concept of Nasdaq stocks to sell won't resonate too kindly with generally optimistic Americans, it's become a reality. It's not just about the fact that on a year-to-date basis, the benchmar
These Were The Five Best And Worst Performing Mid-Cap Stocks In October 2022
08:22pm, Tuesday, 15'th Nov 2022
Mid-cap companies lie in between the slower growth large-cap stocks and the faster-growth small-cap businesses.
PTC Therapeutics: PKU Trial News Likely To Shore Up Share Price
04:08pm, Tuesday, 15'th Nov 2022
The registration-directed phenylketonuria study results are anticipated by the end of the quarter. Management claims there are about 58,000 PKU patients globally that they can target by 2030.
